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Background: Src homology 2 domain containing protein 5 (SH2D5) is a previously uncharacterized protein that resembles
the Shc proteins in structural organization.
Results: SH2D5 binds to the breakpoint cluster region protein (BCR) in a phosphotyrosine-independent manner.
Conclusion: SH2D5 controls neuronal morphology via BCR and Rac1.
Significance: This is the first characterization of SH2D5 in neuronal signaling.
SH2D5 is a mammalian-specific, uncharacterized adaptor-
like protein that contains anN-terminal phosphotyrosine-bind-
ing domain and aC-terminal Src homology 2 (SH2) domain.We
show that SH2D5 is highly enriched in adult mouse brain, par-
ticularly in Purkinjie cells in the cerebellum and the cornu
ammonis of the hippocampus. Despite harboring two potential
phosphotyrosine (Tyr(P)) recognition domains, SH2D5 binds
minimally to Tyr(P) ligands, consistent with the absence of a
conserved Tyr(P)-binding arginine residue in the SH2 domain.
Immunoprecipitation coupled to mass spectrometry (IP-MS)
from cultured cells revealed a prominent association of SH2D5
with breakpoint cluster region protein, a RacGAP that is also
highly expressed in brain. This interaction occurred between
the phosphotyrosine-binding domain of SH2D5 and an NxxF
motif located within the N-terminal region of the breakpoint
cluster region. siRNA-mediated depletion of SH2D5 in a neuro-
blastoma cell line, B35, induced a cell rounding phenotype cor-
related with low levels of activated Rac1-GTP, suggesting that
SH2D5 affects Rac1-GTP levels. Taken together, our data pro-
vide the first characterization of the SH2D5 signaling protein.
Intracellular signaling relies in part on a series of protein-
protein interactions that are often mediated by the recognition
of a modified residue such as a phosphotyrosine (Tyr(P))
through specialized interaction domains, including the Src
homology 2 (SH2)5 and Tyr(P)-binding (PTB) domains (1, 2).
Proteins containing one of these domains often have additional
interaction modules, which enable the proteins to serve as
adaptors, facilitating the recruitment of additional signaling
molecules to regulate intracellular signaling cascades (3). The
SH2 domain-containing protein 5 (SH2D5) is an uncharacter-
ized adaptor-like protein with an N-terminal PTB domain, and
a C-terminal SH2-like domain (4). This domain architecture is
shared with the Shc family of adaptor proteins (see Fig. 1,A and
B). Despite this conserved domain organization, the SH2
domain of SH2D5 lacks the critical arginine (B5) necessary for
Tyr(P) binding. (It is replaced by a tryptophan (5).) SH2D5 also
lacks the YxN motifs that serve as Tyr(P)-docking sites for the
SH2 domain of the Grb2 adaptor (see Fig. 1, A and B).
SH2D5 is a recently evolved, mammalian specific protein (4)
that is highly enriched in brain at the transcript level (6) and has
been detected in phosphoproteomic screens frommurine brain
lysates and postsynaptic density (PSD) fractions (7, 8). How-
ever, there are no functional studies elucidating the biological
role or significance of this protein. Because of the shared
domain architecture of SH2D5withTyr(P) recognition adaptor
proteins, we reasoned that a first step in unraveling the function
of SH2D5 would be to analyze its interaction profiles in
unstimulated cells and cells in which tyrosine phosphorylation
is induced by exposure to pervanadate. Here, we characterize a
novel interaction of the SH2D5 PTB domain with breakpoint
cluster region protein (BCR), a regulator of Rho GTPases (9,
10). We show enrichment of SH2D5 and BCR proteins in neu-
ronal cell types. Finally, we report that SH2D5 depletion in neu-
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ronal cells display low levels of Rac1-GTP and a cell-rounding
phenotype.
EXPERIMENTAL PROCEDURES
Generation of SH2D5 Antibody—A polyclonal antibody was
generated in two rabbits toward the 56 C-terminal amino acids
of mouse (m)SH2D5, expressed as a GST fusion protein in a
pGEX 4T-1 vector, and tested for immunoreactivity. Antise-
rum was affinity-purified using AminoLink Plus Immobiliza-
tion Pierce affinity columns (Pierce catalog no. 44894) accord-
ing to the manufacturer’s instructions. Briefly, two columns
were utilized for affinity purification. For the first column, 6mg
of GST protein were covalently coupled to the AminoLink
resin, and a 1:1 dilution of antisera and PBSwas loaded onto the
column and incubated at 4 °C for 4 h. The second affinity col-
umnwas prepared by coupling 4mg of theGST-fusedmSH2D5
immunogenic peptide. Flow-through from the first columnwas
incubated at 4 °C for 3 h on the second column, and bound
antibody was eluted with 10 1-ml fractions of 1% glycine, pH
1.5–2.0, followed by neutralization with Tris. Fractionated elu-
tions were dialyzed overnight at 4 °C in 4 liters of PBS, and
fractions were tested for yielding the highest titer for mSH2D5
as determined by immunoblot from lysates prepared by tran-
sient transfection of 3FLAG-mSH2D5 into human embry-
onic kidney (HEK)293T cells. High titer fractions for mSH2D5
were pooled, and protein concentration was determined using
the BCA assay. Aliquots of purified antibody were stored at
80 °C until further use.
Plasmids—Full-length mSH2D5 (NCBI accession no. BC036961)
and human (h) SH2D5 (synthesized byGenscript, NCBI RefSeq
no.NP_001096631.1) cDNAswere cloned into aCreator parent
donor vector (Clontech), pDNA MCS SA or pDNA MCS SA
LacZ  using the restriction sites AscI and PacI. Utilizing the
Cre-recombinase reaction (11), full length h- or mSH2D5 were
excised into donor vectors containing an N-terminal 3FLAG
tag, N-terminal 2Myc tag, N-terminal mCherry, or citrine
(11). The W321R mutation within the hSH2D5 SH2 domain
was prepared by site-directedmutagenesis using the Stratagene
QuikChange kit (no. 200522-5) and sequence-verified.Deletion
mutants of mSH2D5 were prepared by PCR amplification of
various regions of full length protein, whereas the PTB and SH2
domain boundaries were defined by the SMART database (12).
PCR fragments were cloned into creator donor vectors and
spliced intoN-terminal 3FLAG tag orN-terminal 2Myc tag
acceptor vectors. Mutations within BCRwere prepared by site-
directedmutagenesis using the StratageneQuikChange kit (no.
200522-5): N179A/F182A/N252A/F255A within the N-termi-
nal region. All mutations were sequence-verified.
Cell Culture, Transfection, and Stimulation—HEK293T
cells, DLD-1, K562, KBM-3, Neuro2A, and B35 were cultured
in Dulbecco’s modified Eagle’s medium or modified Eagle’s
medium supplementedwith 10% fetal bovine serum (HyClone).
Cells were transiently transfected using polyethyleneimine,
Lipofectamine 2000 (Invitrogen), or RNAi Max (Invitrogen)
andwhen required treatedwith 0.1mMpervanadate for 40min.
Pervanadate was prepared by combining sodium orthovana-
date and hydrogen peroxide for 10min on ice, prior to applying
to intact cells. Activity of pervanadate was verified by probing
lysates for phosphotyrosine by immunoblot.
Lysate Preparation and Immunoblotting—Lysates were pre-
pared from wild-type male C57BL/6 mice tissues, age 4–6
weeks, HEK293T orNeuro2A cells.Murine tissues and cell pel-
lets were lysed in 50 mM HEPES, pH 7.5, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 15mMMgCl, supplemented with 10
g/ml aprotinin, 10g/ml leupeptin, 1 mM sodium vanadate, 1
mM PMSF and 1 mM DTT. Murine brain samples were lysed in
a glass homogenizer, and protein concentration was deter-
mined by the BCA assay, and concentrations were normalized
accordingly. Whole brain lysates for endogenous immunopre-
cipitations were prepared by solubilizing murine whole brains
in 1% Triton X-100, 50 mM HEPES, pH 7.5, 150 mM NaCl,
freshly supplemented with protease inhibitors 10 g/ml apro-
tinin, 10 g/ml leupeptin, 1 mM sodium vanadate, 1 mM phe-
nylmethylsulfonyl fluoride, and 1 mM dithiothreitol.
PSDs were prepared from male C57BL/6 mice, age 6–8
weeks, using a procedure modified from Dunah et al. (13).
Briefly, whole brains were resuspended in 0.32 M sucrose, 4 mM
HEPES pH 7.4, supplemented with protease and phosphatase
inhibitors (10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM per-
vanadate, 1 mM phenylmethylsulfonyl fluoride, hereafter
referred to as buffer 1). Homogenate was centrifuged at 4 °C for
10 min at 10,000  g (Allegra 12F Beckman Coulter), and the
pellet, P1 (nuclei, cellular debris) was saved. The supernatant
(S1) was centrifuged again for 15 min at 4 °C at 12,000  g
(BeckmanUltracentrifuge,MLA-80), and the supernatant from
this spin was denoted S2 (synaptosome depleted fraction). The
pellet P2 (crude synaptosomal fraction) was rinsed in 50 mM
HEPES, pH 7.4, 2 mM EDTA, supplemented with protease and
phosphatase inhibitors, hereafter referred to as buffer 2. The P2
fraction was then resuspended again in buffer 2. The slurry was
centrifuged for 20 min at 4 °C at 32,000  g (Beckman Ultra-
centrifuge, MLA-80), and the supernatant LS1 (synaptosomal
cytosolic fraction) was collected. The pellet LP1 (mitochondria,
pre- and postsynaptic membranes) was washed with buffer 2
and resuspended again in buffer 2. Fractions S2 and LS1 were
centrifuged again for 2 h at 4 °C at 165,000 g (BeckmanUltra-
centrifuge, MLA-80). Supernatants were then collected and
termed S3 (cytosol) and LS2 (synaptosol).
Pellets from this spin were resuspended in buffer 2 and son-
icated using a Probe Sonicator (VibraCell SonicsMaterial, Inc.)
at an amplitude of 50 at 4 °C for 5–10-s pulses, and slurries were
denoted P3 (microsomes) and LP2 (crude synaptic vesicle frac-
tion), respectively. LP1 was then washed in buffer 2, resus-
pended again in buffer 2 and sonicated for 5–10 s. TritonX-100
was then added to a final concentration of 1% to LP2 samples
that were incubated on ice for 1 h. Solutions were then spun for
20 min at 4 °C at 32,000  g (Beckman Ultracentrifuge, MLA-
80), and the supernatant PSD S1 (Triton extracted postsynaptic
density supernatant 1) was collected. The pellet PSDI (Triton
extracted insoluble postsynaptic density fraction) was resus-
pended in buffer 2, and sodium lauroyl sarcosinate and sarcosyl
were added to a final concentration of 3% each. Samples were
centrifuged for 1 h at 4 °C at 200,000  g (Beckman Ultracen-
trifuge, MLA-130), and the supernatant was collected, termed
PSDII (Triton and sarcosyl postsynaptic density fraction).
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Antibodies used for immunoblotting or immunoprecipita-
tion were obtained from the following commercial sources:
mouse monoclonal anti-Tyr(P) 4G10 (Millipore catalog no.
05-321), mouse monoclonal anti-FLAGM2 (Sigma catalog no.
3165), rabbit polyclonal anti-BCR N-20 (Santa Cruz catalog
no. 885 andCell SignalingTechnology catalog no. 3901),mouse
monoclonal anti-PSD 95 (Abcam catalog no. 7ES-1B8), mouse
monoclonal anti-tubulin DM1A (Sigma catalog no. 9026),
mousemonoclonal c-Myc 9E10 (SantaCruzBiotechnology cat-
alog no. 40), rabbit polyclonal anti-GFP (Abcam catalog no.
290), mouse monoclonal anti-Rac1 23A8 (Millipore catalog no.
05-389), andmousemonoclonal GAPDH (Cell Signaling Tech-
nologies catalog no. 14C10).
Immunohistochemistry of Brain Sections—Whole brains
from wild-type male C57BL/6 mice, age 6–8 weeks, were fixed
in 4% paraformaldehyde PFA andmounted in paraffin sections.
SH2D5 antigen retrieval was conducted by incubating slides for
20 min in 10 mM sodium citrate buffer, followed by a PBS wash
for 5 min. Blocking was carried out with Dako protein block,
serum-free, for 30min (Dako, catalog no. X0909). Purified anti-
SH2D5 was used at a 1:50 dilution and incubated overnight at
4 °C, followed by three PBS washes for 5-min each. Slides were
incubated in secondary antibody, biotinylated goat anti-rabbit
IgG (1:200, Vector Laboratories, BA-1000), for 30 min at room
temperature followed by three washes in PBS for 5-min each.
Slides were then counterstained with hematoxylin (1.0 g/liter)
for 30 s.
Deparaffinization for BCR immunohistochemistry IHC was
carried out using xylene I, II, and III for 5-min each. Slides were
rehydrated in 100% ethanol and double-distilled water for 5
min. Antigen retrieval was conducted using proteinase K (10
g/ml) for 30 min at room temperature, followed by three
washes in PBS. Blocking was carried out with a Dako protein
block (Dako, catalog no. X0909). Primary anti-BCR antibody
(Cell Signaling Technology, catalog no. 3901) was incubated in
a 1/50 dilution at 4 °C overnight followed by three washes in
PBS for 5-min each.
Immunoprecipitation and Mass Spectrometry Analysis—
Immunoprecipitations were carried out using 2 g of anti-
FLAG mouse monoclonal antibody (Sigma catalog no. 3165)
with 10 l of packed protein G beads, 2 g of anti-GFP rabbit
polyclonal (Abcam catalog no. 290) with 10 l of packed pro-
tein A-Sepharose beads, or 2 g of anti-c-Myc mouse mono-
clonal (Santa Cruz Biotechnology, catalog no. 40) with 10 l of
packed proteinA-Sepharose. For all immunoprecipitations, the
antibody and the beads were added simultaneously to the cell
lysates. Immunoprecipitations were carried out for 2 h at 4 °C
on a Gyro Mini nutating mixer (LabNet S0500). Unbound pro-
teins were removed by three washes in lysis buffer for 10 min
each at 4 °C. For immunoblot analysis, proteins were eluted by
boiling beads in 2 SDS sample buffer for 10 min. For mass
spectrometry analysis, bait and prey proteins were eluted from
the beads using 90l of 0.2% phosphoric acid and digested on a
strong cation exchange column.
All mass spectrometry experiments were performed on a
QSTAR Elite QqTOF mass spectrometer equipped with a
nanospray III ion source (AB Sciex Concord, ON, Canada),
coupled to an Eksigent 1D Nano LC (Dublin, CA). Samples
were injected directly onto in-house “packed tip” columns. A
4-m tip was pulled at the end of a 25-cm piece of 360 m,
inner diameter 75m fused silica tubing using aModel 2000
Micropipette Laser Puller (Sutton InstrumentCo.). Amethanol
slurry of 3 m of ReprosilGold 120 C-18 stationary phase
medium was prepared in a 1.5-ml glass vial and placed into a
pressure bomb. 120mmof stationary phasewas packed into the
360 m, inner diameter  75 m fused silica pulled-tip using
the pressure vessel set at 1500 psi. Samples (at an injected vol-
ume of 7 l) were run using a 90-min gradient from 5–30%
solvent B (solvent A, water with 0.1% formic acid; solvent B,
acetonitrile with 0.1% formic acid) at a flow rate of 250 nl/min.
Samples were injected into the mass spectrometer in the fol-
lowing order: control sample, followed by bait protein sample.
Standard BSA injections were run between samples to limit
cross-contamination.
For database searches, acquired RAW files were converted to
mascot generic format (mgf) files using the ProteoWizard (14)
tool with default parameters and were searched with Mascot
(Matrix Sciences, London, UK, version 2.3) against the RefSeq
database (version 42 for human (total entries searched, 39,125)
and version 41 for mouse (total entries searched, 36,378)).
Searches were performed on the mgf files with carbamidom-
ethyl (C) set as a fixed modification and deamidation (NQ),
oxidation (M), phosphorylation (S/T), and phosphorylation (Y)
set as variable modifications. Trypsin was selected for enzyme
digestionwith up to twomissed cleavages. Pulsar type fragmen-
tation was selected with peptide mass tolerance set to 100 ppm
and fragment mass tolerance set to 0.15 Da. As a negative con-
trol, FLAG-GFP immunoprecipitations were performed in
bothHEK293T andNeuro2A in amanner similar to the SH2D5
pulldowns to detect background contaminants. The results
from Mascot were then run through the Trans Proteomics
Pipeline (15) using the ProHits interface (16).
Identified proteins were filtered as follows: first, the proteins
that were found in negative control pulldowns were removed.
We then removed known contaminants in similar FLAG puri-
fications (17) as well as antibody, keratin, and albumin proteins.
Proteins with a Trans Proteomics Pipeline ProteinProphet
score0.95 andwith at least eight peptides identified in at least
one experiment were kept in our data sets. For generating the
list of interactors, we mapped the mouse proteins identified
onto their humanorthologs using theMGI database. To further
reduce the probability of including frequent flyer proteins in
our final list, we used an additional strict filtering technique. In
this method, background proteins identified in 15% of sam-
ples analyzed in the Pawson laboratory (550 samples)6 were
removed from the data set. Lastly, only proteins detected across
both the Neuro2A and the HEK293T cell lines were kept; this
resulted in only two proteins, the SH2D5 bait, as expected, and
the breakpoint cluster region protein BCR.
RNA Interference of SH2D5—SH2D5 levels were depleted in
the rat neuroblastoma cell line B35 using Dharmacon SMART
Pool ON-TARGETplus reagents (Dharmacon, Thermo Scien-
tific, Lafayette, CO). Cells were seeded in a 24-well plate at a
6 E. J. Gray, E. Petsalaki, D. A. James, R. D. Bagshaw,M. M. Stacey, O. Rock, A.-C.
Gingras, and T. Pawson, unpublished data.
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density of 1.7 105 cells/well in antibiotic-free medium and at
the time of seeding were transfected with 50 nM of siRNA using
Lipofectamine RNAi Max according to manufacturers proto-
col. GAPDH, scrambled siRNA, and the deconvoluted siRNAs
from the SH2D5 SMARTPool were transfected at a 50 nM
concentration.
GST-PAK-RBD Pulldown Assays—Levels of activated Rac1
weremeasured by utilizing a standard glutathione S-transferase
p21-activated kinase-Rac binding domain (GST-PAK-RBD)
binding assay, which selects for activated levels of endogenous
Rac1. B35 neurons were seeded at a density of 8  106 cells/
15-cm plates and at the time of seeding, cells were depleted of
SH2D5 using siRNA as above. Cells were lysed in 1 ml of RBD
lysis buffer: 1% Nonidet P-40, 10% glycerol, 50 mM Tris-HCl
(pH 7.5), 15 mM MgCl2, 150 mM NaCl, freshly supplemented
with 1 mM DTT, 10 g/ml of aprotinin, 10 g/ml of leupeptin,
100 mM sodium vanadate, and 100 mM PMSF. Lysates (quanti-
fied by the BSA assay) were incubated for 45min with 120l of
GST-PAK-RBD corresponding to 25 g of protein. Beads were
pelleted by centrifugation at 3000 rpm for 5 min, the superna-
tant discarded, and beads were washed three times with RBD
buffer for 5min each. Beadswere then boiled in 70l of 2 SDS
sample buffer, and proteins resolved on an SDS-PAGE gel were
transferred to a PVDF membrane for immunoblot detection
using specific antibodies.
RESULTS
SH2D5 Expression in Brain—Tomonitor SH2D5 expression,
we generated a rabbit polyclonal antibody toward the last
C-terminal 56 amino acids of mSH2D5 (Fig. 1, A and C). In an
immunoblot, the SH2D5 antibody readily recognized overex-
pressed recombinant human (h) and mSH2D5 from a total cell
lysate of HEK293T cells (Fig. 1D). We then examined endoge-
nous SH2D5 protein expression inmurine tissues. SH2D5 has a
predicted molecular mass of 47 kDa, and a possible second iso-
form is predicted at 37 kDa because of an alternative initiator
methionine (this form should also be recognized by our anti-
body). We find a single 47-kDa SH2D5 isoform that is highly
expressed in brain (Fig. 1E).
SH2D5 BindsMinimally to Tyr(P) Proteins but Interacts with
BCR—Given the unusual nature of the SH2D5 SH2 domain
(Fig. 1A), we assessed whether SH2D5 could bind proteins in a
phosphotyrosine-dependent manner. HEK293T cells were
transiently transfected with 3FLAG-tagged mSH2D5, and
FIGURE 1. Domain architecture of the SH2D5 protein and expression pattern. A, two isoforms of SH2D5 are predicted (black arrows). The longer SH2D5
isoform contains an N-terminal PTB (blue underline) and C-terminal SH2 domain (green underline). The SH2 domain lacks the critical arginine necessary for
phosphotyrosine binding (red arrow). A 56-amino acid antigen (black underline) was used to generate a rabbit polyclonal antibody toward SH2D5. B, SH2D5
shares a similar domain architecture to the Shc adaptor.C, constructs utilized for characterizing the SH2D5antibody. Adeletionmutant ofmSH2D5 (TM), which
is missing the antigenic region (red underline) was used as a negative control. D, the SH2D5 antibody recognizes overexpressed recombinant h- andmSH2D5
in immunoblot. E, SH2D5 expression in tissue lysates from C57B/6 WT mice aged 4–6 weeks. The FLAG tag results in a 3-kDa mass shift for recombinant
mSH2D5 compared with endogenous mSH2D5, which migrates at 47 kDa.WB, Western blot.
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intact cells were treated or not treatedwith 0.1mMpervanadate
for 40 min to increase cellular Tyr(P) levels (Fig. 2A). SH2D5
was immunoprecipitated with anti-FLAG antibodies, and
lysates were immunoblotted with an anti-Tyr(P) antibody.
SH2D5 boundminimally to Tyr(P) proteins compared with the
Grb2 adaptor, which bindsmultipleTyr(P)-containing proteins
through its SH2 domain. The only Tyr(P) protein associating
with SH2D5 migrated at 160 kDa (Fig. 2A) (see “Discussion”).
We attempted to restore SH2 domain Tyr(P) binding bymutat-
ing the tryptophan found at the B5 position (residue 321) to
arginine, but mutagenesis of this residue did not increase the
ability of SH2D5 to enrich tyrosine phosphorylated proteins,
suggesting that its SH2 domain may have additional defects in
Tyr(P) recognition (Fig. 2A).
We used immunoprecipitation coupled to mass spectrome-
try (IP-MS) to identify binding partners for SH2D5. HEK293T
and Neuro2A cells were transiently transfected with 3FLAG-
mSH2D5, and cells were treated or not with pervanadate.
SH2D5 was immunoprecipitated with anti-FLAG antibodies,
and precipitated proteins were identified using liquid chroma-
tography coupled tomass spectrometry. Consistently, across all
cell lines and regardless of Tyr(P) levels, BCR was identified as
the strongest interaction partner of SH2D5 (Fig. 2B andTable 1;
see “Experimental Procedures”).
SH2D5 Binding to BCR Is Not Tyr(P)-dependent—BCR is a
multidomain protein with an N-terminal region, also referred
to as a pseudokinase domain, followed by RhoGEF, pleckstrin
homology, C2, and RhoGAP domains. Although BCR contains
both a GEF and a GAP domain, the activity of the GEF domain
is ambiguous (18, 19). BCR is 68% homologous to ABR (active
BCR-related), but ABR lacks the N-terminal region present in
BCR (Fig. 3A) (20). To address whether the SH2D5 and BCR
interaction is Tyr(P)-dependent, HEK293T cells were trans-
fected with 3FLAG-mSH2D5, and cells were treated with
pervanadate or left untreated. Lysates were immunoprecipi-
tated with anti-FLAG antibodies to enrich for SH2D5, and
immunoprecipitates were probed for endogenous BCR. SH2D5
bound endogenous BCR regardless of Tyr(P) levels, suggesting
a Tyr(P)-independent interaction (Fig. 3B).We then probed for
the SH2D5-BCR interaction in mouse brain by immunopre-
cipitating endogenous SH2D5 or BCR from mouse brain
lysates. Indeed, BCR was detected in the endogenous SH2D5
FIGURE 2.Characterizationof thebindingproperties of SH2D5.A, as SH2D5 lacks the criticalB5 arginine necessary for Tyr(P) ligand recognition,mutagen-
esis was used to reintroduce the arginine residueW321R. HEK293T cells were transiently transfected with 3FLAG-tagged Grb2 (lanes 1 and 5), FLAG-tagged
green fluorescent protein (GFP) (lanes 2 and 6), 3FLAG-tagged hSH2D5 (lanes 3 and 7), or 3FLAG-taggedW312R SH2D5 (lanes 4 and 8). Intact cells were left
untreated (lanes 1–4) or treated with 0.1 mM pervanadate for 40 min (lanes 5–8). Proteins were immunoprecipitated with FLAG antibodies, and lysates were
probed with an anti-Tyr(P) (pTyr) antibody (middle panel). A tyrosine-phosphorylated protein resolving at160 kDa, is present in the wild-type and W321R
SH2D5 immunoprecipitate (red arrow). B, results of the immunopurification coupled to mass spectrometry experiments. Human HEK293T cells or mouse
Neuro2A cells were transiently transfected with 3FLAG-tagged hSH2D5 and treated (or not) with pervanadate as described above. FLAG IP-MS was per-
formed as detailed under “Experimental Procedures.” BCR and the SH2D5 bait were the only two proteins detected across the two different cell lines. Their
spectral counts, unique number of peptides (as searched in the human or mouse library, respectively), and sequence coverage (in percentage) are listed.WB,
Western blot.
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immunoprecipitates, and SH2D5 could be detected in the
endogenous BCR immunoprecipitates. Neither BCR nor
SH2D5 were detected in the rabbit IgG negative control (Fig.
3C). To ensure that the anti-SH2D5 antibody was not binding
directly to BCR, we performed immunoprecipitations against
recombinant FLAG-tagged full-length SH2D5 and the FLAG-
tagged truncated SH2D5 mutant, which lacks the region to
which the antibody was raised. We then probed the immunob-
lots for BCR. BCR is only detected in the full-length SH2D5
immunoprecipitate, and not with the truncated mutant, sup-
porting the notion that the anti-SH2D5 antibody does not
cross-react with BCR (Fig. 3D).
The PTB Domain of SH2D5 Interacts with a Specific NxxF
Motif within the N-terminal Region of BCR—We mapped the
region of SH2D5 necessary for binding BCR using a series of
3FLAG-tagged deletionmutants ofmSH2D5 (Fig. 4A). These
experiments showed that the PTB domain of SH2D5 is both
necessary and sufficient to bind full-length endogenous BCR
(Fig. 4B). Similarly, we made deletion mutants of BCR to
address which region is recognized by the SH2D5 PTB domain
(Fig. 4C) and found that the N-terminal region of BCR was
sufficient to bind both full-length SH2D5 and its isolated PTB
domain (Fig. 4D). PTB domains commonly recognize motifs
containing a core NPxY sequence, but whereas some PTB
domains only efficiently recognize such sites once they are
phosphorylated, not all PTB domains require Tyr(P) for bind-
ing (21). For example, the Numb PTB domain binds NxxF
motifs (22). TheN-terminal region of BCR lacksNPxY sites, but
contains two NxxF sequences in this region, NVEF and NPRF,
respectively. To test whether these NxxF motifs in BCR may
serve as ligands for the SH2D5 PTB domain, we mutated their
asparagine and phenylalanine residues to alanines and tested
for the ability of variants containing individual or double NxxF
site mutations to bind SH2D5 (Fig. 4E). The resulting data
showed that themoreC-terminalNxxFmotif in theN-terminal
region of BCR is necessary for binding to the SH2D5 PTB
domain and to the full-length protein, whereas the N-terminal
motif appears to be dispensable (Fig. 4, E–G).
SH2D5 and BCR Expression—As BCR is expressed in brain
and is enriched in the PSD (9), we compared SH2D5 expression
with that of BCR. Both proteins were found throughout differ-
ent brain regions though their expression pattern did not fully
overlap (Fig. 5A). Interestingly, SH2D5 expression increases
through development and reaches a maximum in adult brain.
We found that BCR expression decreases through development
(Fig. 5, B and C), which is supported by Oh et al. (9), who
observed decreased levels of BCR expression as mice age. It is
tempting to speculate that this differential expression may be
due to mutual regulation, although this remains to be investi-
gated. We also found that both SH2D5 and BCR share partial
enrichment in the PSD (Fig. 5D). There again, however, the
overlap is only partial: SH2D5 is readily extracted in the PSD
soluble fraction with Triton X-100 and shows enrichment in
the pellet (PSD1). Although BCR is also found in the same frac-
TABLE 1
mSH2D5 interaction partners assembled fromoverexpressing 3FLAG-taggedmSH2D5 in either humanembryonic kidney (293T) cells treated
with or without 0.1 mM pervanadate for 40 min
mSH2D5 was immunoprecipitated with FLAG antibodies, and interactors were identified via liquid chromatography/mass spectrometry. Interactors are listed with
common names (interactor ID), unique peptide counts, sequence coverage (%), and the TransProteomics Pipeline (TPP) score. Data are significant at TPP score,0.95, and
were generated using an additional filtering step (refer to “Experimental Procedures” section). Proteins that were identified in the mouse cell line Neuro2A were mapped
onto their human orthologs.
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tion, it is also abundant in the second extraction with Triton
X-100 and sarcosyl, which may be due to the existence of dif-
ferent pools of BCR in the PSD, only some of which coinciding
with the SH2D5 pool. In coronal brain sections of C57B/6 WT
mice, both proteins share similar expression patterns and are
enriched in purkinje cells in the cerebellum (Fig. 5E) as well as
in pyramidal cells in the cortex. Further enrichment is found for
both proteins in the cornu ammonis regions of the hippocam-
pus. As ameasure of specificity, these signals were absent when
the SH2D5 antibody was pre-adsorbed with excess antigen.
Taken together, we conclude that both SH2D5 and BCR share
similar expressions patterns in brain and show a partial local-
ization within the post-synaptic density.
SH2D5 Depletion in Neurons Reveals a Cell-rounding Pheno-
type and Reduced Levels of Rac1-GTP—To investigate the func-
tion of SH2D5 at the cellular level, we first examined a panel of
FIGURE 3. Validation of the SH2D5-BCR interaction. A, BCR contains an N-terminal region (NT) and GEF, PH, C2, and GAP domains. B, HEK293T cells were
transiently transfected as indicated with 3FLAG-tagged Grb2 (lanes 1 and 4), 3FLAG-tagged pEGFP (lanes 2 and 5) or with 3FLAG-tagged SH2D5 (lanes 3
and 6). Intact cells were treated with (lanes 4–6) or without (lanes 1–3) 0.1 mM pervanadate for 40 min. Proteins were immunoprecipitated with FLAG
antibodies, and lysates were probed for endogenous BCR (left). Endogenous BCR was expressed at similar levels (right; top) and recombinant proteins were
precipitated in similar levels (right; bottom). C, endogenous IPs from murine brain lysates were performed from C57B/6 WT mice (4–6 weeks). Endogenous
SH2D5 was immunoprecipitated with the anti-SH2D5 antibody, and lysates were immunoblotted for endogenous BCR (second top panel). Endogenous BCR
was immunoprecipitatedwith an anti-BCR antibody, and lysateswere immunoblotted for endogenous SH2D5 using the anti-SH2D5 antibody (top panel). BCR
is detected in the SH2D5 immunoprecipitate (top panel, lane 1), and a faint band corresponding to SH2D5 is present in the BCR immunoprecipitate (top panel,
lane 3, red asterisk). Equal expression levels of endogenous BCR and SH2D5 are observed (two lower panels, lanes 1–3). The IgG heavy chain is indicated as IgG.
D, to ensure that the SH2D5 antibodywas not bindingdirectly to BCR, HEK293T cellswere transfectedwith FLAG-tagged full-length (FL) SH2D5 (lane 3) and the
truncated mutant (TM) lacking the region to which the SH2D5 antibody was raised (lane 5; see Fig. 1C for schematic). Recombinant SH2D5 was immunopre-
cipitatedwith anti-SH2D5antibodies, and lysateswereprobed for BCR (toppanel). TCL, total cell lysate.Asteriskmarks thepositionof theSH2D5band in theBCR
immunoprecipitate.
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FIGURE 4. The SH2D5 PTB binds an NxxF motif within BCR. A, truncated mutants of mSH2D5 were cloned into an N-terminal 3FLAG-tagged vector;
selected constructs were also cloned into Myc or GFP expression vectors. B, FLAG-tagged SH2D5 deletionmutants were transiently transfected into HEK293T
cells, andproteinswere immunoprecipitatedwith anti-FLAGantibodies. Thepresenceof endogenousBCR in the immunoprecipitates (second and third panels)
was assayed by BCR immunoblot. Total BCR levels were detected by immunoblotting total cell lysates (TCL) of BCR (bottom panel). The minimum element
required to immunoprecipitateBCR is theSH2D5PTBdomain (lane 13).C, full-length (FL) BCRwas cloned into anN-terminalGFPexpressingvector andmutants
were cloned into an N-terminal 3FLAG-tagged vector.D, FLAG-tagged truncatedmutants of BCR and the full-length protein were co-expressed in HEK293T
cells along with full-length mSH2D5 and the SH2D5 PTB domain (tagged with a Myc epitope). The N-terminal region of BCR is sufficient to recruit the SH2D5
PTBdomain andFL-SH2D5 (lanes 4 and 8,bottompanel). E, BCRmutations, in a FLAG-taggedvector, aredefinedas follows:N179A, F182A (NF1), N252A, F255A
(NF2); and both NxxFmotifs are defined as follows: N179A, F182A, N252A, and F255A (NF4). F, FL-SH2D5 and the SH2D5 PTB domainwere immunoprecipi-
tated with GFP antibodies and show equal levels of immunoprecipitation (bottom panel). Themiddle band in this panel is the IgG heavy chain. The FL-SH2D5
and the PTB domain are found in thewild-type andNF1 BCR immunoprecipitates, as verified by a GFP immunoblot, lanes 1, 2, 5, and 6, second panel from the
bottom. Yet, the NF2 and NF4 fail to immunoprecipitate FL-SH2D5 and the PTB domain, lanes 3, 4, 7, and 8, second panel from the bottom. Neither the
FL-SH2D5 nor the PTB domain recruits the NF2 and NF4 mutant, suggesting that the second NxxF motif is required for the SH2D5-BCR interaction. G,
FL-SH2D5was cloned into a FLAG vector and the FL-BCR-NF2was generated in a GFP vector. Wild-type FL-BCR immunoprecipitates FL-SH2D5; however, the
NF2 FL-BCR does not.
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cell lines (data not shown) and found endogenous expression of
SH2D5 in a B35 neuronal cell line. B35 cells are derived from a
rat neuroblastoma and provide a useful model system to ascer-
tain the functional significance of neuronally enriched proteins.
Using these cells, we depleted endogenous levels of SH2D5,
using the Dharmacon individual siRNAs to SH2D5 in compar-
isonwith theDharmacon SMARTpool and a scrambled control
(Fig. 6, A and B). The siRNA pool resulted in a nearly 50%
FIGURE 5. Comparison of BCR and SH2D5 expression patterns in brain. A, lysates were prepared from C57B/6 WT mice aged 4–6 weeks. B and C,
developmental expression of BCR and SH2D5 in brain lysates from embryonic (E), postnatal (P), and 4- or 8-week-old mice. Lane 1 in both A and B is a positive
control for the SH2D5 antibody, comprised of overexpressed FLAG-tagged full-length SH2D5 in HEK293T cells. D, BCR and SH2D5 expression in postsynaptic
density; nuclei/cellular debris (P1), supernatant (S2), crude synaptosomal fraction (P2), cytosol (S3), microsomal membranes (P3), synaptosomal cytosolic
fraction (LS1), synaptosol (LS2),mitochondria, pre- andpostsynapticmembranes (LP1), crude synaptic vesicle fraction (LP2), PSD fractions extractedwith Triton
X-100once and supernatant collected (PSDSI), pellet (PSDI), and extractedwith TritonX-100 and sarcosyl (final concentration, 3%; PSDII). E, immunohistochem-
istry on coronal brain sections of cerebellum, cortex, and hippocampus. Both SH2D5 and BCR are enriched in Purkinjie cells (PC, top panel). The cerebellar
nuclear layer hasbeen stainedbluewithhematoxylin. SH2D5andBCRexpression inpyramidal cells (PYC) of the cortex,whereBCR is enriched inpyramidal cells
comparedwithSH2D5 (middle panel). Finally, SH2D5andBCR showexpression in the cornuammonis (CA) regionsof thehippocampus (bottompanel). No signal
is detected upon using rabbit IgG, as a negative control. Likewise, pre-absorption of the anti-SH2D5 antibody, abrogates antibody detection for SH2D5
(blocked anti-SH2D5). DG, dentate gyrus.WB, Western blot.
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reduction of endogenous SH2D5, whereas siRNA 19 had a dra-
matic effect on SH2D5 levels. Upon reducing SH2D5 levels,
neurons appeared rounded and grew in a lattice formation.
This phenotype was not observed in the scrambled negative
controls, in untransfected cells or in the individual siRNAs that
did not deplete SH2D5 levels (Fig. 6C and data not shown).
Attempts to rescue this phenotype with full-length SH2D5
were unsuccessful as cell growth was highly compromised at
this stage of the experiment. As low levels of Rac-GTP regulate
neuronal cell rounding and BCR has been shown to be a nega-
tive regulator of Rac (18, 23), we investigated whether Rac1-
GTP levels were affected upon SH2D5 depletion in B35 cells by
performing PAK pulldown assays. Indeed, a reduction in
endogenous SH2D5 resulted in decreased levels of activated
Rac1 (Fig. 6, D and E).
DISCUSSION
In mediating protein-protein interactions, adaptors bind
various types of signaling effectors, including regulators of the
actin cytoskeleton such as guanine exchange factor proteins
(GEFs) and activating GTPase-activating proteins (GAPs).
GEFs andGAPs regulate the activity of small GTPases, wherein
GEFs promote the activity of small GTPases and GAPs display
an inhibitory effect. In this study, we have characterized an
interaction between SH2D5 and BCR, a regulator of Rho
GTPases (9, 10) displaying GAP activity toward Rac, Rho, and
Cdc42 proteins (18, 23).
The PTB domain of SH2D5 engages with one of two NxxF
motifs in the N-terminal region of BCR, a binding property
demonstrated by other PTB domains. For instance, the Numb
PTB domain binds Numb-associated kinase through an NxxF
motif (24) and to Numb-interacting protein through two tan-
demNxxFmotifs on Numb-interacting protein (25). hJIP1 also
binds to p190-RhoGEF, through a PTB-NxxF interaction (26),
whichmay regulate the cellular localization of p190-RhoGEF in
developing neurites.
Our data indicate that theTyr(P)-independentmodeof bind-
ing demonstrated by the SH2D5 PTB domain extends to the
SH2 domain, as anticipated by the lack of the key B5 arginine
residue required for Tyr(P) recognition by conventional SH2
domains. Yet, while elucidating the binding properties of
SH2D5, a tyrosine-phosphorylated protein resolving at 160 kDa
was detected in both the wild type and W321R SH2D5 immu-
noprecipitates, suggesting that SH2D5 could indeed recognize
FIGURE 6. Effect of SH2D5 depletion on themorphology of B35 rat neuroblastoma cells. A, comparison of SH2D5 depletion using 50 nM of nontargeting
scrambled and individual SH2D5 siRNAs. The knockdown efficiency of endogenous SH2D5 is 50% at maximum with the SH2D5 pool. As controls, the
individual siRNAs from theDharmacon SMARTpool (siRNA 17, 18, 19, 20)were compared against the SH2D5pool alongwith amock (no siRNA control) andWT
cells. B, the individual siRNA no. 19 results in nearly a complete reduction of endogenous SH2D5 (lane 2). C, images of B35 neurons upon 72 h of siRNA
transfection as described in A. Cells display a clustered, rounding phenotype, when depleted of SH2D5. Images were taken at 10magnification. D, B35 cells
depleted of SH2D5 were assessed for Rac1-GTP levels. Cells were treated with appropriate siRNA and 72 h post-transfection, and GST-PAK assays were
performed. As controls, lysates were immunoblotted for levels of total Rac, BCR, and SH2D5. E, cells depleted of SH2D5 display reduced levels of Rac1-GTP by
60%, compared with untreated cells (n 2). The experiment was also repeated using a scrambled siRNA control, which had no effect on activated levels of
Rac1, total Rac1, total SH2D5, and total BCR (not shown). AU, arbitrary units;WB, Western blot.
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Tyr(P) ligands. However, BCR is tyrosine-phosphorylated at
Tyr-177, which is a docking site for the Grb2 SH2 domain (27).
Given that BCR migrates at 160 kDa and would be tyrosine-
phosphorylated when intact cells are treated with pervanadate,
as was performed in this experiment, we hypothesize that the
tyrosine phosphorylated protein identified in the wild type and
W321R SH2D5 immunoprecipitates is BCR (and that the inter-
action does not depend upon the Tyr(P)). Given that cell lines
were used in these experiments, we cannot rule out that other
bona fide Tyr(P) targets of either the SH2D5 PTB or SH2
domain do exist (e.g. in PSD).
SH2D5 depletion in neuronal cells was associated with low
levels of Rac1-GTP, an observation accompanied by a cell
rounding phenotype, which can occur with low levels of acti-
vated Rac (28). Neuronal phenotypes associated with altered
levels of Rac and Rho include aberrations in cell rounding and
adhesion along with neurite outgrowth and retraction (28, 29).
Mice deficient for neuronal Rac1 andRac3 die around postnatal
day 13, due to impaired brain development from a reduction of
axons and dendrites within the hippocampus. Furthermore,
neurogenesis and synaptogenesis within the hippocampus are
impaired and axonal projections are reduced in the hippocam-
pus of these mutant mice (30).
In summary, our data support a broader notion that SH2D5
expression in the PSD, its associationwith BCR and its effect on
Rac-GTPmay impact synaptic plasticity, which is important for
learning and memory.
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